Invivyd faces a significant regulatory hurdle after the Food and Drug Administration moved to terminate the emergency use authorization for Pemgarda, its Covid-19 prevention medication. The designation is scheduled to expire on June 29 of next year, putting immediate pressure on the company's product pipeline.
In section Market Quotes
Healthcare Sector Stumbles as Tech Optimism Drives Rotation
A broader exodus from defensive assets hit healthcare stocks this week as market sentiment swung toward high-growth technology equities. The sector-wide retreat underscores a shifting risk appetite among investors, who are increasingly favoring aggressive tech positions over the relative stability of traditional life-science and medical services companies.
Meanwhile, London-based Clarivate saw its shares drop following the announcement of a $600 million divestiture. The provider of analytics and workflow solutions is selling its life-science and healthcare arm to New York-based investment firm Altaris. Clarivate leadership stated the exit is designed to sharpen the company's focus on AI-driven intelligence tools tailored for academic, government, and intellectual-property markets.
Comments (0)
No comments yet. Be the first!